A Phase 2 interventional study of Shared decision-making and amoxicillin-clavulanate in Acute Appendicitis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Appendicitis with a site in France — 7 open to participants now, 7 under way, 2 of them phase 3. Appendicitis · France.
Among the 18 studies in Appendicitis with a site in France, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 2, and was the 18th registered.
421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.
Browse Appendicitis studies →7 of the 18 studies in Appendicitis with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France, Reunion
Ages 15–74
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 5–14
University Hospital, Angers · Sites in France
Ages 3–16
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 560 is above the median of 116 across 254 interventional studies indexed under Appendicitis.
Median enrollment 473 across the 13 interventional studies, 100 across the 5 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 18 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 2 studies filed under Appendicitis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Appendicitis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ALACARTE study evaluates a strategy in which patients with acute uncomplicated appendicitis are given the choice between appendectomy and antibiotic therapy alone. The investigators hypothesize that giving patients the choice of treatment could reduce treatment regret without compromising safety, particularly by not increasing the risk of complicated appendicitis.Treatment regret will be assessed one year after the randomization. A public health benefit is also anticipated through cost reduction, as antibiotic therapy alone is expected to be less costly than surgery.
Appendectomy provides definitive treatment for acute appendicitis. However, antibiotic therapy alone represents an alternative treatment option for patients with acute uncomplicated appendicitis.Patients are centrally randomized in a 1:1 ratio to either the "Patient Preference Treatment" group or the "Systematic Appendectomy" group.In the "Patient Preference Treatment" group, patients receive information through a video, followed by a discussion with the investigator and a reflection period of at least 30 minutes. Patients may then choose between antibiotic therapy alone and appendectomy. Patients who do not make a treatment choice undergo appendectomy.The study is based on the hypothesis that giving patients a choice of treatment could reduce treatment regret without compromising safety, particularly by not increasing the risk of complicated appendicitis.Treatment regret will be assessed one year after the randomization.
Inclusion Criteria:
Diagnosis of uncomplicated AA established by the investigator surgeon that relies on clinico-biological suspicion of acute AA confirm by care radiological tests (US and/or CT and/or MRI) including appendix diameter >6.0mm. and without:
i. Free air ii. Walled off fluid collection concerning for an abscess iii. Significant amounts of intra-abdominal fluid throughout abdomen (i.e.,more than trace fluid) iv. Extent of inflammation or adjacent organ involvement on radiologic, appendicular plastron on radiologic imaging
Exclusion Criteria:
Exclusion Criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive standardized information and are then allowed to choose between antibiotic therapy alone and appendectomy. Patients who do not express a preference undergo appendectomy.
Other: Shared decision-making · Drug: amoxicillin-clavulanate · Procedure: Appendectomy
Participants undergo appendectomy as the standard treatment for acute uncomplicated appendicitis
Procedure: Appendectomy
Participants receive standardized information and are then allowed to choose between antibiotic therapy alone and appendectomy. Patients who do not express a preference undergo appendectomy.
Drug pages: AmoxicillinStudies of AmoxicillinAmoxicillin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Clavulanic AcidStudies of Clavulanic AcidClavulanic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
amoxicillin-clavulanate (PO or IV 1 gx3/day for patients \<90 kg or 1 gx4/day for patients ≥90 kg)
Also known as: amoxicillin-clavulanic acid
Appendectomy
Regret about the initial treatment
The presence of regret about the initial treatment will be evaluated through a specific questionnaire completed online by the patient. The question will be: "You were initially treated for your appendicitis (infection of the appendix) either by surgery with removal of the appendix (appendectomy) or by antibiotic therapy alone without surgery initially. Do you regret the treatment you received? YES - NO." The surgeon will be blinded to the answer.
Time frame: 12 month after the randomization
Patient's symptom persistence or recurrence
Proportion of patients with at least one symptom persistence or recurrence at 12 months : Symptom persistence defined by participants who report the persistence of significant abdominal pain (≥4 with intensity quantified using the numeric pain rating scale from 0 to 10), the persistence of a perceived or measured fever \> 38.0°C, or the persistence of chills.
Time frame: at 12 months
Patient's quality of life at 12 months.
Quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). questionnaire using the French value set for scoring heath states and fulfilled by the participants (Responses are recorded on a 5-point scale: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems or unable to perform the activity.)
Time frame: at 12 months
Regret concerning the treatment received
The regret at 12 months assessed by the validated decisional regret scale. This standardized scale allows quantifying treatment regret by a score ranging from 0 for no regret to 100 for maximum regret.
Time frame: at 12 months
Diagnosis of a complicated AA
Complicated AA is defined by a localized or diffuse peritonitis, abscessed appendicitis, necrotized appendicitis or appendicular plastron as determined by the surgeon through intraoperative findings or through clinical examination and abdominal imaging (CT-scan or MRI or abdominal US) in case of non-surgical management.
Time frame: within 12 months after randomization
Positive bacteriological examination of intrabdominal fluid harvested during surgery
Time frame: during surgery
Overall 12-months morbidity
The occurrence of at least one of the following complication during the 12 months after randomization: site-related infectious complications (defined as incisional infections or organ-space infections \[abscesses\]), percutaneous drainage procedure, surgical intervention (for complication after appendectomy or appendectomy for recurrent appendicitis after antibiotic), ileus requiring the placement of a nasogastric tube, wound hernia, small bowel obstruction requiring emergency consultation or hospitalization, adverse event related to the known side effects of the administered antibiotic therapy.
Time frame: 12 months
Unscheduled medical encounter
by at least one of the following events: * Unscheduled consultations or readmissions at hospital related to the AA or to its treatment reported by the participant. * Among patients treated initially by appendectomy: proportion of patient with unscheduled surgical procedures due to delayed complications after appendicitis or appendectomy. * Among patients treated initially by antibiotics only: proportion of occurrence of appendectomy (with or without appendicitis on the surgical specimen) or unscheduled surgical procedure other than appendectomy due to complications related to the AA. * Among patients treated initially by antibiotics only: proportion of recurrence or persistent AA proven by pathological examination of the appendix after appendectomy or by an imaging (CT or ultrasound or MRI) in case of nonsurgical management.
Time frame: within 12 months after randomization
Diagnosis of an appendicular tumor
Presence of an appendicular tumor (benign or malignant) defined by the anatomopathological diagnosis on the operative specimen of appendectomy.
Time frame: within 12 months after randomization
Cost per quality-adjusted life year (QALY) gained
Economic evaluation comparing patients who had the option to select their treatment versus patients who underwent systematic appendectomy. Results will be expressed as cost per QALY gained at 12 months.
Time frame: at 12 months
Cost per additional patient without complication
Economic evaluation comparing patients who had the option to select their treatment versus patients who underwent systematic appendectomy. Results will be expressed as cost per additional patient without complication at 12 months.
Time frame: at 12 months
Patient's regret
assessed by the answer at the question : " : "You were initially treated for your appendicitis (infection of the appendix) either by surgery with removal of the appendix (appendectomy) or by antibiotic therapy alone without surgery initially. Do you regret the treatment you received? YES - NO."
Time frame: at 1 and 6 months
Treatment regret assessed by the validated decisional regret scale.
This standardized scale allows quantifying treatment regret by a score ranging from 0 for no regret to 100 for maximum regret.
Time frame: at 1 and 6 months
Persistence of appendicitis-related symptoms assessed by abdominal pain, fever, or chills
Symptom's persistence defined by participants who report the persistence of a significant abdominal pain (≥4 with intensity quantified using the numeric pain rating scale from 0 to 10), the persistence of a perceived or measured fever \> 38.0°C, or the persistence of chills.
Time frame: at 1 and 6 months
Patient's quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) at 1 month and 6 months
Quality of life assessed by the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). questionnaire using the French value set for scoring heath states and fulfilled by the participants (Responses are recorded on a 5-point scale: 1 = no problems, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = extreme problems or unable to perform the activity.)
Time frame: at 1 and 6 months
Number of participants reporting each potential cause of treatment regret, assessed using a 13-item self-administered questionnaire
Potential causes of treatment regret assessed using a 13-item self-administered questionnaire evaluating information and understanding before treatment, decision-making process, treatment experience, and social and economic consequences. Each item is scored from 1 (strongly agree) to 5 (strongly disagree).
Time frame: at 12 months
12-month overall length of stay
Time frame: within 12 months after the randomization
12-month duration of sick leave related to the AA or to its treatment.
Time frame: within 12 months after the randomization
Therapeutic adherence to the treatment (Among patients initially treated by antibiotics only)
Among patients initially treated by antibiotics only: Therapeutic adherence to the treatment defined by the complete intake of the prescribed antibiotic doses over a duration of 7 days. This criterion will be assessed by the following question at 1 month: "Regarding the antibiotic treatment prescribed, have you?: 1) Taken all prescribed doses, 2) Missed some doses but at least 75% of the treatment was taken, 3) Missed some doses but between 25% and 75% of the treatment was taken, 4) Missed some doses with less than 25% of the treatment taken"
Time frame: at 1 month
Pain intensity at the time of the treatment decision assessed by the Numeric Pain Rating Scale (patient preference treatment group)
Pain intensity on an 11-point Numeric Pain Rating Scale from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more pain. Presence or absence of fever, nausea and vomiting recorded at the same time.
Time frame: at inclusion
Main motivation for the treatment decision assessed by a self-administered questionnaire (patient preference treatment group)
Self-administered questionnaire completed after the treatment decision: main reason for choosing antibiotic therapy alone or appendectomy (8 options), or for choosing not to decide (4 options).
Time frame: at inclusion
Decisional conflict assessed by the Decisional Conflict Scale (patient preference treatment group)
16-item validated Decisional Conflict Scale. Total score from 0 (no decisional conflict) to 100 (extremely high decisional conflict); higher scores indicate greater decisional conflict.
Time frame: at inclusion
Healthcare access and lifestyle assessed by a self-administered questionnaire (patient preference treatment group)
Self-administered online questionnaire on travel time to the general practitioner and to the hospital, living conditions, occupational status, educational level, use of primary care and sources of health information.
Time frame: at 1 month
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Nov 2029, 37 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amoxicillin · Clavulanic Acid
Assistance Publique - Hôpitaux de Paris →